The Precision Spectra SCS, which the company claims is the world’s first and only device with Illumina 3D software and 32 contacts, features an implantable pulse generator that delivers electrical pulses to leads with stimulating contacts.
Barolat Neuroscience medical director Giancarlo Barolat said: "When combined with 32 contacts and four lead ports — twice that of any other SCS system — the Precision Spectra technology gives physicians more flexibility to customize therapy for patients."
The programmable software embedded in the device is based on a proprietary computer model that takes into account 3D anatomical structures, including the conductivity of the spinal cord and surrounding tissue, said the company.
The software is expected to improve control of the stimulation field by creating a customised stimulation to mask pain signals travelling to the brain.
To further understand the needs of chronic pain patients, the company initiated a prospective, multicentre, single-arm OPTIONS trial to characterise the benefits of having a 32-contact option in the Precision system.
Another trial, including a cross-sectional, multicentre MAP study, will estimate the prevalence of multiple areas of pain in SCS-eligible patients with certain diseases.
Boston Scientific neuromodulation business unit president Maulik Nanavaty said: "The launch of the Precision Spectra System demonstrates our commitment to bringing meaningful innovations to market that provide more pain relief to a broader spectrum of patients."
In addition, the company has introduced Precision Plus SCS System for head-only MRI use and peripheral nerve stimulation, Vercise Deep Brain Stimulator system for Parkinson’s disease and Infinion 16 Percutaneous SCS Lead in the US and Europe.
Image: Boston Scientific’s Precision Spectra SCS delivers electrical pulses to treat chronic pain. Photo courtesy of Boston Scientific.